Skip Navigation

European Heart Journal 2003 24(3):209-211; doi:10.1016/S0195-668X(02)00754-6
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Morice, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morice, M. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Hotline Editorial

A new era in the treatment of coronary disease?

Marie Claude Morice*

Institut Cardiovasculaire Paris Sud, Institut Hospitalier Jacques Cartier, 6 avenue du Noyer Lambert, 91300 Massy, France

* Tel.: +33-1-60134601; fax: +33-1-60134603
mc.morice@icps.com.fr

The first 150 words of the full text of this article appear below.

1. Introduction

The technique of coronary stenting introduced in the early 1990s contributed widely to the enhancement of percutaneous interventions' outcomes in patients with coronary artery disease.

However, the phenomenon of in-stent restenosis has long been the stumbling block of interventional cardiology and the target of many research projects in this field including the use of various devices or radiation therapy, and systemic or local delivery of biochemical substances and drugs.

Indeed, angiographic restenosis, defined as a stenosis or narrowing of the vessel diameter by ≥50% at follow-up evaluation (binary restenosis), is still reported in 17–30% of patients followingcardiac stenting with uncoated or bare stents.1,2 Restenosis following stenting is largely due toneointimal hyperplasia, which is the healingresponse to the vascular injury induced by stent implantation and mechanical dilatation and translates into proliferation of smooth muscle cells.3–6 It is in this context that the technology of site-specific, stent-based drug delivery to inhibit the . . . [Full Text of this Article]

2. Are drug-eluting stents cost-effective?

3. The clinical implications


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Journal of Bioactive and Compatible PolymersHome page
R. T. Pijls, L. H. Koole, H. H.L. Hanssen, and R. M.M.A. Nuijts
Flexible Coils with a Drug-Releasing Hydrophilic Coating: A New Platform for Controlled Delivery of Drugs to the Eye?
Journal of Bioactive and Compatible Polymers, July 1, 2004; 19(4): 267 - 285.
[Abstract] [PDF]